2022 World Conference on Lung Cancer (ePosters)-EP08.01-025. PD-L1 Tumor Tissue Expression and Its Relation with Clinico-pathological Profile in Advanced NSCLC

EP08.01-025. PD-L1 Tumor Tissue Expression and Its Relation with Clinico-pathological Profile in Advanced NSCLC

Pdf Summary

This study aimed to investigate the prevalence of PD-L1 expression and its relationship with clinicopathological parameters in patients with stage IV non-small cell lung cancer (NSCLC) from a tertiary care center in Eastern India. The study included 94 patients with stage IV NSCLC, with 44.7% showing PD-L1 positivity. The median overall survival in the cohort was 6.5 months, which was not significantly different between the PD-L1 positive and negative groups. However, patients with PD-L1 positivity had significantly increased rates of advanced tumor stage and higher nodal stage. There were no statistically significant differences in PD-L1 positivity with respect to gender, age group, and smoking habits. EGFR mutations were seen in 29.8% of patients, while 4.2% were ALK positive. PD-L1 positivity was observed in 46.4% of EGFR positive patients and 44% of EGFR negative patients, with no significant difference between the two groups. Overall, 45% of stage IV NSCLC patients in the cohort showed PD-L1 positivity. PD-L1 positivity was not associated with patient demographics but was associated with more aggressive tumor characteristics. Further research is needed to understand the role of PD-L1 expression in guiding treatment decisions and predicting outcomes in NSCLC patients.

Asset Subtitle

Sindhu Kilaru

Meta Tag

Speaker Sindhu Kilaru

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

PD-L1 expression

prevalence

clinicopathological parameters

stage IV NSCLC

overall survival

tumor stage

nodal stage

EGFR mutations

ALK positive

aggressive tumor characteristics